Luspatercept for rare inherited anemias
Part of Blood & lymphatic clinical trials.
This study tests a drug called luspatercept to see if it can improve anemia in people with rare inherited red blood cell disorders. It may help reduce the need for blood transfusions or raise hemoglobin levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a rare inherited anemia (sideroblastic anemia, dyserythropoietic anemia, or Diamond-Blackfan anemia) with a confirmed genetic cause.
- Depending on your anemia type, you either need regular blood transfusions, or you have low hemoglobin but receive transfusions only occasionally.
- Your kidneys and liver must be in good working order as shown by blood tests.
- If you have Diamond-Blackfan anemia, you must not need regular transfusions, and your genetic mutation must be in certain specific genes (RPS19, RPS26, RPL5, or RPL11).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
This trial tests whether luspatercept, given as the first treatment, can help people with a blood condition called myelodysplastic neoplasms who need regular red blood cell transfusions. It may reduce transfusion needs and improve blood counts.
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
This trial tests whether luspatercept can help improve low red blood cell counts (anemia) that happens soon after a stem cell transplant. It is for people with blood cancers who have very low hemoglobin after transplant.
This Phase 2 trial studies luspatercept to improve anemia (low red blood cells) in people with MDS that has a del5q change. It also checks safety, especially for people who need red blood cell transfusions and have not benefited from prior standard treatments.
Hear when a new Hereditary Red Blood Cell Disorder (Disorder) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.